Navigation Links
Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
Date:1/28/2009

Pace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia early in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure early in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure and our intent to write a new chapter in the development of proprietary pharmaceuticals that treat urgent medical needs. The forward-looking statements are subject to risks and uncertainti
'/>"/>

SOURCE Duska Therapeutics, Inc.; Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Inhibikase Therapeutics, Inc., an emerging ... it will present new results on its antiviral ... sponsored by the PML Consortium (composed of Pfizer, ... (JCV) is the causative agent of Progressive Multifocal ... in an extended release formulation, can clear JC ...
(Date:5/23/2013)... 23, 2013 InspireMD, Inc. ... leader in embolic protection stents, today announced new ... ST Elevation Reperfusion) trial demonstrating that the MGuard ... drug eluting stents in all-cause mortality in ST ... the trial were presented at the InspireMD STEMI ...
(Date:5/23/2013)... and PARIS , May 23, ... a leading developer and manufacturer of precision guided therapy ... coronary and peripheral vascular disease, today announced preliminary results ... I ndependent S tenosis E valuation) ... trial session at EuroPCR 2013. These prospective results confirm ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5
... BAY, Wis., Sept. 7, 2011 ... solutions to hospitals, IDNs, healthcare systems and clinics, ... of the Centers for Medicare & Medicaid Services ... Medical Documentation (esMD).  (Logo: http://photos.prnewswire.com/prnh/20110907/PH63482LOGO) ...
... 7, 2011 As NFL coaches and players face a ... one team,s preparation will be gaining a competitive edge as ... season. Today, Polar USA and the Atlanta Falcons announced that ... "Official Heart Rate Training System" of the Atlanta Falcons. ...
Cached Medicine Technology:IOD to Enter Testing Phase in CMS esMD Pilot Program 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 3
(Date:5/23/2013)... a study in 2012 suggested a cancer drug ... with Alzheimer,s disease, three groups of researchers now ... findings. The teams said their research could ... drug involved in the study, bexarotene (Targretin), has ... pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, ...
(Date:5/23/2013)... Emory Vaccine Center have shown that an immune regulatory ... in mice against viral infections. , The results are ... "Our findings highlight how IL-21 could be important in ... Ur Rasheed Mohammed, PhD, the first author of the ... of the Emory Vaccine Center and a Georgia Research ...
(Date:5/23/2013)... Chicago, IL (PRWEB) May 23, 2013 ... of comprehensive solutions and educational resources for the ... today that it is opening its first global ... in the Philippines in August. This new world-class ... the best of Western evidence-based practices to treat ...
(Date:5/23/2013)... 23, 2013 Six innovative research projects ... by Lyme Research Alliance, the nation's largest private nonprofit funder ... studies focus on the epidemiology of, and treatment and ... “LRA is proud to support the innovative research being ... men and women in the field today,” said Harriet ...
(Date:5/23/2013)... researchers examining outcomes for advanced heart-failure patients over ... with the increased availability and use of new ... death, caused by the rapid onset of severe ... However, the team found that even today, with ... more than three years after being diagnosed with ...
Breaking Medicine News(10 mins):Health News:Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3
... For immediate release -- Sept. 22, 2011 (Toronto) -- A ... recommends a public health approach to cannabis - including evidence-based ... that result from the use of cannabis. Led ... (Simon Fraser University, Vancouver) Dr. Benedikt Fischer, the study is ...
... class of medicines commonly given for pain -- were associated ... 3,061 adults, aged 65 to 94, e-published in advance of ... . The study from researchers at Group Health Research Institute ... which are drugs generally given for insomnia and anxiety, did ...
... 22 (HealthDay News) -- There were 134 waterborne disease ... in the United States in 2007-08, and 36 outbreaks ... released Thursday. The 134 recreational water illness outbreaks ... in 38 states and Puerto Rico, caused at least ...
... , THURSDAY, Sept. 22 (HealthDay News) -- Almost 7 percent of ... hospitalized within 30 days of the procedure, a new study indicates. ... who do not get prostate biopsies can expect to be hospitalized, ... Journal of Urology . "The overall hospitalization rate is about ...
... , THURSDAY, Sept. 22 (HealthDay News) -- Over-the-counter asthma ... layer, will not be made or sold after Dec. ... The sole product affected is Primatene Mist, marketed ... inhaler approved by the FDA to be sold without ...
... - The University of Kentucky,s Dr. Susanne Arnold and colleagues ... study potential environmental reasons for the high lung cancer rates ... three years and the study began on Sept. 15. ... but counties in the southeastern portion of the state ...
Cached Medicine News:Health News:New study proposes public health guidelines to reduce the harms from cannabis use 2Health News:New study proposes public health guidelines to reduce the harms from cannabis use 3Health News:Opioids linked to higher risk of pneumonia in older adults 2Health News:Infections Linked to Swimming, Drinking Water: CDC 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 3Health News:Asthma Inhaler Primatene Mist Going Off the Market 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 3
... multichannel pipettes speed up ... into microplates, with super ... volumes. The improved ergonomic ... multichannels, combined with super ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
Medicine Products: